Trial intelligence / Profile preview

AMBITION 1

2026-525470-18-00Phase 3Authorised

Sponsor: Novo Nordisk
Start: Nov 2026
Modality: Small Molecules, Peptides
Countries: 7

Overview

Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Zenagamtide with Placebo (2 arms). Primary endpoint: Change in glycated haemoglobin (HbA1c). Planned start Nov 2026; status: authorised.

Drugs

amycretin

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on 2026-525470-18-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2026-525470-18-00.